<SEC-DOCUMENT>0001558370-23-017507.txt : 20231103
<SEC-HEADER>0001558370-23-017507.hdr.sgml : 20231103
<ACCEPTANCE-DATETIME>20231103083546
ACCESSION NUMBER:		0001558370-23-017507
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231103
DATE AS OF CHANGE:		20231103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		231374584

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glyc-20231103x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.4.0.13 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/2/2023 9:51:04 PM -->
      <!-- iXBRL Library version: 1.0.8630.22539 -->
      <!-- iXBRL Service Job ID: 1f939b4c-7216-4c98-9e26-f2a33f18b5a9 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://www.glycomimetics.com/20231103" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:EntityCentralIndexKey" id="Tc_Wyl-mzv8X0CdwmgVwvhvyg_2_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:AmendmentFlag" id="Tc_PKlggHJc80ud0WSLqSUrcg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="glyc-20231103.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-03</xbrli:startDate><xbrli:endDate>2023-11-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-top:9pt double #000000;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><a id="_0a72fd11_d0c7_486d_a868_6d91db0833f2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">UNITED STATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">FORM </b><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:DocumentType" id="Narr_PNpLuo6n6EKOUL_S1kx6oQ"><b style="font-weight:bold;letter-spacing:-0.1pt;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;">Date of Report (Date of earliest event reported):</b><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_M0yLh30QXkyhtVANhsC4gg"><b style="font-size:9pt;font-weight:bold;">November 3, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:EntityRegistrantName" id="Narr_OT416jFlgUWPs83yrh0ysg"><b style="font-weight:bold;letter-spacing:-0.1pt;">GlycoMimetics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_e1f4de58_61bd_4709_b865_8049cd6378dd"></a><a id="Tc_aEZZLeqWQ06by6Emze6VFg_2_0"></a><a id="Tc_DabyNzwq70OCk3q8R1hzuw_2_2"></a><a id="Tc_Dfn-zH5-mk2WYPay4Cox5g_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_YgzXbu4LzkuZsKsmU5no3A_1_0"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:EntityFileNumber" id="Tc_Ydga4oleTk-x6NhTg2q1cQ_1_2"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">001-36177</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:EntityTaxIdentificationNumber" id="Tc_vlP3FNEImkeOPFnhrmx0Yw_1_4"><b style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">06-1686563</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(State or other jurisdiction of</span> <span style="letter-spacing:-0.1pt;">incorporation)</span></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(IRS Employer</span><br /><span style="letter-spacing:-0.1pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:EntityAddressAddressLine1" id="Narr_PoSp81GyxE6_2KUaZ9sLmA"><b style="font-size:9pt;font-weight:bold;">9708 Medical Center Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:EntityAddressCityOrTown" id="Narr_au77FcctMUOIuOcIuLDAHA"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:EntityAddressStateOrProvince" id="Narr_gI1XIHDOGUm_Bhrbcidi6A"><b style="font-size:9pt;font-weight:bold;">MD</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:EntityAddressPostalZipCode" id="Narr_8JYiLpr3MEiJXVAf6Wuylg"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Address of principal executive offices, including zip code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:CityAreaCode" id="Narr_eVqJafHtzU6gV5NuxdjWAw"><b style="font-size:9pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:LocalPhoneNumber" id="Narr_Fx3UpzhxzkGBzF5xC76YnQ"><b style="font-size:9pt;font-weight:bold;">243-1201</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Former name or former address, if changed since last report)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_j8a8rgBV7EG3txS8e1Pvww"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_LnmH6372q0ymUOv4fdkGqA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_q0j95xb16kyf2Fg3Ahq_kw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_5WutMF3BQUaMwP7XE2hqog"><span style="font-family:'Segoe UI Symbol';font-size:9pt;letter-spacing:0pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;letter-spacing:0pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_815aaab8_f3ad_460f_b7c2_43bd0f552b4c"></a><div style="margin-left:0pt;"><a id="Tc_6xRHNcUw9EWQYnOYOCdUXA_1_0"></a><a id="Tc_oO5pNaDWfUClPybJ2-XeIA_1_1"></a><a id="Tc_ai3A1HFRnEqj1feOtiIsbw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of each class</b></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:Security12bTitle" id="Tc_R2fnw-sIjUWiUYWUMnDAyg_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" name="dei:TradingSymbol" id="Tc_aI8tM4d9o0K15tI1cZY3LA_2_1"><span style="font-size:9pt;">GLYC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_qAZeN6yBq0OcHYSNZnBGbw_2_2"><span style="font-size:9pt;">The Nasdaq Stock Market</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_kNcGGEYWcUirjk3CEzqykA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Courier New';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_6ae6eebd_08cb_4ec5_9034_e675a12c6c88"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 2.02 &#160;</b></span><b style="font-weight:bold;">Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On November 3, 2023, GlycoMimetics, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span><i style="font-style:italic;">&#8221;)</i><span style="font-style:italic;font-weight:bold;"> </span>issued a press release announcing its financial results for the third quarter ended September 30, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company&#8217;s filings under the Securities Act of 1933, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Securities Act</span>&#8221;), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01</b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (d)&#160;Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td></tr><tr style="height:3.55pt;"><td style="vertical-align:top;width:10.27%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">9</span>9.1</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="glyc-20231103xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated November 3, 2023, &#8220;GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023&#8221;</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.05pt;margin:0pt;"><span style="font-size:0.05pt;visibility:hidden;">&#8203;</span></p><a id="_b63a899d_8572_44e2_92f7_f1598448e000"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;text-align:justify;text-indent:37.05pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.7pt;padding-right:0.7pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></div></div></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GLYCOMIMETICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;">By:&#160;&#160;</span></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">/s/ </span>Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:-0.1pt;white-space:pre-wrap;">Date:  November </span>3, 2023</p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian M. Hahn<br />Senior Vice President and Chief Financial Officer </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>glyc-20231103xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/2/2023 09:51:01 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;text-transform:uppercase;margin:0pt 41.75pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"><img src="glyc-20231103xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:58.4pt;width:271pt;"></b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by end of Q2 2024</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">NDA filing for uproleselan anticipated by end of 2024 pending outcome of R/R AML pivotal study</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Initial results for GMI-1687 Phase 1a study expected by end of Q1 2024 with initial focus to develop highly potent E-selectin antagonist as point-of-care treatment in sickle cell disease </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Updated independent clinical data exploring potential of uproleselan in difficult to treat subtype of AML to be presented at the American Society of Hematology (ASH) meeting in December</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Conference call and webcast today at 8:30 a.m. ET </font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">ROCKVILLE, Md.--(BUSINESS WIRE) &#8211; November 3, 2023-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023. Cash and cash equivalents as of September 30, 2023 were $49.4 million.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">&#8220;We look ahead to 2024 with anticipation and excitement. Topline results for our pivotal Phase 3 study of uproleselan in relapsed/refractory AML remain on track by the end of Q2 and together with our potential NDA filing before the end of 2024 represent a transformational opportunity for patients, clinicians, and our company,&#8221; said Harout Semerjian, Chief Executive Officer of GlycoMimetics. &#8220;Our progress toward these important milestones, along with the upcoming presentation of independent data on uproleselan at ASH and the expected initial results of our Phase 1a GMI-1687 study by end of Q1 2024, demonstrate our ability and ambition to deliver our development strategy and move closer to becoming a commercial stage company.&#8221;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Operational Highlights</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Uproleselan</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Hlk130828815"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In Q2, GlycoMimetics announced U.S. Food and Drug Administration (FDA) clearance of a protocol amendment to the company&#8217;s pivotal Phase 3 study of uproleselan for R/R AML. This amendment provides for a time-based analysis of the primary endpoint of overall survival after a defined cutoff date, if the 295 survival events of the originally planned event-driven analysis have not been observed by that date. With the addition of the time-based analysis, the company expects topline results by the end of Q2 2024.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 18pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">The National Cancer Institute (NCI) Alliance for Clinical Trials in Oncology will conduct a planned interim analysis of event-free survival in 267 patients randomized to its Phase 2/3 clinical trial (NCI protocol A041701) evaluating uproleselan in newly diagnosed older adults with AML who are fit for chemotherapy. Enrollment of the Phase 2 portion of the study was completed in December of 2021. The company reiterates that when available, it will share these results.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Hlk140751440"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">The company agreed with the European Medicines Agency on a Pediatric Investigational Plan (PIP), which followed the prior agreement with the FDA in Q2 2023 on an initial Pediatric Study Plan (iPSP). The PIP and iPSP each include a deferral for study completion, and a waiver for children less than 28 days of age.  As part of the pediatric plans, an NCI sponsored Phase 1/2 pediatric trial is currently being conducted by the Children&#8217;s Oncology Group Pediatric Early Phase Clinical Trials Network. The Phase 1/2 dose escalation study (NCI protocol PEPN2113) evaluates the safety and preliminary activity of uproleselan plus fludarabine and high dose cytarabine in pediatric AML patients after two or more prior therapies. The first patient in the Phase 1 portion of the study has been dosed with an expected enrollment of 18 patients. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Updated clinical data from an investigator-initiated trial studying the use of uproleselan in combination with chemotherapy for patients with treated secondary AML has been accepted for poster presentation at the ASH Annual Meeting in December.  Investigators at MD Anderson Cancer Center are conducting the Phase 1b/2 clinical trial to evaluate safety, tolerability, and preliminary efficacy of uproleselan added to cladribine and low dose cytarabine in patients with this difficult to treat subset of AML. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">GMI-1687</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">In August, GlycoMimetics initiated a Phase 1a double-blind, single-center, randomized, placebo-controlled, sequential, single ascending dose trial in healthy adult volunteers. It is expected to enroll approximately 40 subjects. Eligible subjects will receive a single dose of GMI-1687 or placebo (6:2 ratio) via subcutaneous injection.  Safety, tolerability, and pharmacokinetics of up to five dose levels (3.3, 10, 20, 40, and 80 mg) will be evaluated. GMI-1687 is a highly potent E-selectin antagonist that has potential application in inflammatory diseases with initial focus on sickle cell disease. Initial results are expected by the end of Q1 2024.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Quarter 2023 Financial Results:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Cash position: As of&#160;September 30, 2023,&#160;GlycoMimetics&#160;had cash and cash equivalents of&#160;$49.4 million&#160;as compared to&#160;$47.9 million&#160;as of&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">December 31, 2022.  </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">R&amp;D Expenses: The company&#8217;s research and development expenses increased to&#160;$5.3 million&#160;for the quarter ended&#160;September 30, 2023,&#160;as compared to&#160;$4.9 million&#160;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">for the same period in 2022.  The increased expenses were primarily due to the clinical development costs related to the Phase 1a trial of GMI-1687 in healthy adult volunteers, which was initiated in August 2023; the increase was partially offset by decreased personnel-related and stock-based compensation costs due to a lower number of personnel than in the prior year. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">G&amp;A Expenses: The company&#8217;s general and administrative expenses increased to&#160;$4.5 million&#160;for the quarter ended&#160;September 30, 2023,&#160;as compared to&#160;$3.8 million&#160;for the same period in 2022. The increased expenses were primarily due to higher personnel-related expenses and higher professional fees as the company advances uproleselan and prepares for potential regulatory filing and commercialization.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Shares Outstanding: Shares of common stock outstanding as of September 30, 2023 were 64,368,843.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="white-space:pre-wrap;">The company will host a conference call and webcast today at 8:30 a.m. ET.  To access the call by phone, please go to this</font> registration link<u style="color:#0563c1;text-decoration-color:#0563c1;text-decoration-line:underline;text-decoration-style:solid;">,</u> and you will be provided with dial in details.&#160;Participants are encouraged to connect 15 minutes in advance of the scheduled start time. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">A live webcast of the call will be available on the &#8220;Investors&#8221; tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="display:inline-block;width:173.5pt;"></font><font style="margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About Uproleselan</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class E-selectin antagonist. Uproleselan (yoo&#8217; pro le&#8217;se lan), currently in a broad development program including a late-stage Phase 3 trial in acute myeloid leukemia (AML), has received Breakthrough Therapy and Fast Track designations from the FDA and Breakthrough Therapy designation from the Chinese National Medical Products Administration for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin binding and stimulation of myeloid cells. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect. Uproleselan is intended to enable a novel approach to disrupting established mechanisms of leukemic cell resistance. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><a name="_Hlk140751818"></a><b style="font-weight:bold;">About GMI-1687</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">Discovered and developed by GlycoMimetics, GMI-1687 is a highly potent E-selectin antagonist that has been shown in animal models to be fully bioavailable following subcutaneous administration. This second-generation compound is currently being studied in a Phase 1a double-blind, single-center, randomized, placebo-controlled, sequential, single ascending dose trial in healthy adult volunteers. GMI-1687 is believed to have potential application in inflammatory diseases, and the company&#8217;s initial development focus is treatment of sickle cell disease (SCD). E-selectin is believed to play a major role in vaso-occlusive crisis (VOC), the vascular clots and blockages that cause pain crises in people living with SCD. Administration of GMI-1687 via subcutaneous injection, if successfully developed in the clinic, may enable the drug to address current challenges of IV therapies for SCD as well as offer a potential point-of-care treatment option at the onset of VOC.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">About GlycoMimetics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company&#8217;s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates.  The company&#8217;s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of and data from clinical trials; planned or potential clinical development, regulatory interactions or submissions, and pre-commercialization activities; and the potential benefits and impact of the company&#8217;s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing&#160;GlycoMimetics, please see the risk factors described in the Company&#8217;s Annual Report on Form 10-K filed with the&#160;U.S. Securities and Exchange Commission&#160;(SEC) on&#160;March 29, 2023, and other filings&#160;GlycoMimetics&#160;makes with the&#160;SEC&#160;<font style="white-space:pre-wrap;">from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Investor Contact: </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Argot Partners</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Leo Vartorella </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;">212-600-1902</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">Glycomimetics@argotpartners.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-weight:bold;margin-bottom:10pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Public Relations Contact:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">Geoff Cook</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;">973-652-7927</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">geoff@cookgm.co</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Condensed Statements of Operations</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands, except share and per share data)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 41.75pt;"><font style="visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:35.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.72%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Revenue from collaboration and license agreements</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 75</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">Research and development expense</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,292</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,923</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,783</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 22,500</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">General and administrative expense</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,522</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,845</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,901</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,356</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 9,814</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,768</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 29,684</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 36,856</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (9,814)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (8,768)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (29,684)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (36,781)</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Interest income </p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 611</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 244</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,864</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 336</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (9,203)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (8,524)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (27,820)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (36,445)</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss per common share &#8211; basic and diluted</p></td><td style="vertical-align:bottom;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.14)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.16)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.44)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.70)</font></p></td></tr><tr><td style="vertical-align:bottom;width:35.76%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding &#8211; basic and diluted</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 64,349,709</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 52,423,944</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 62,992,006</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 52,387,561</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Balance Sheet Data</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 49,408</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 47,871</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Working capital</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 45,619</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 41,834</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 53,201</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 51,811</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 6,653</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,881</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#39; equity</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 46,548</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 42,930</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>glyc-20231103xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20231103xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !. 6D# 2(  A$! Q$!_\0
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MUL<'(Y##K[Y%>=>#O!_A7Q#I(FO_ !*-*OD)$L$^Q!UX*EC\W&/?.:ZCX?\
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M5-.O7^?>\9C0#[V\J,QG _I@GBN_\7^(O"^H^"3=ZG.MUH]YA8S$#O=L_P
MX(8$'Z8.:\4OKA/AOK5G?>%O$*:E;7 WF)#\P4$?)*O3G/'0]>!Q1@Z<:E*4
M%32DV]TVO2_2P8ZI*E6A4=5N"2VDD_6W6Y].45FZEXBT_18K1]2NH['[4XCC
M$S8^;&<$]NG4\=/45H@A@"#D'D$5\VXM)-K<^I4HMM)ZH^0?V\?^2E?LQ_\
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MW\%_!GQS\+/X?\:Z';ZUIV[S(C)E9;>3&-\4BX9&]P>1P<@D5VU% 'RMI/\
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=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>glyc-20231103.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/2/2023 9:51:08 PM-->
<!--Modified on: 11/2/2023 9:51:08 PM-->
<xsd:schema targetNamespace="http://www.glycomimetics.com/20231103" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:glyc="http://www.glycomimetics.com/20231103" xmlns:cef-pre="http://xbrl.sec.gov/cef-pre/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20231103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20231103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/cef/2023" schemaLocation="https://xbrl.sec.gov/cef/2023/cef-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cef-pre/2023" schemaLocation="https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="glyc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>glyc-20231103_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/2/2023 9:51:08 PM-->
<!--Modified on: 11/2/2023 9:51:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="glyc-20231103.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="glyc_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>glyc-20231103_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/2/2023 9:51:08 PM-->
<!--Modified on: 11/2/2023 9:51:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20231103.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cef/2023/cef-2023.xsd#N2" roleURI="http://xbrl.sec.gov/cef/role/N2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20231103.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638345586683561316" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638345586683561316" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638345586683561316" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638345586683561316" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638345586683561316" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638345586683561316" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638345586683561316" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638345586683561316" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638345586683561316" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638345586683561316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638345586683561316" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638345586683571310" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638345586683571310" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638345586683571310" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638345586683571310" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638345586683571310" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638345586683571310" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638345586683571310" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638345586683571310" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638345586683571310" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638345586683571310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638345586683571310" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638345586683581298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638345586683581298" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638345586683581298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638345586683581298" order="22" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cef/role/N2" xlink:type="extended" xlink:title="995470 - Disclosure - N-2" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139978464754928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_glyc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139978460372144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>N-2<br></strong></div></th>
<th class="th"><div>Nov. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>glyc-20231103x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20231103.xsd" xlink:type="simple"/>
    <context id="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Tc_Wyl-mzv8X0CdwmgVwvhvyg_2_1">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Tc_PKlggHJc80ud0WSLqSUrcg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_PNpLuo6n6EKOUL_S1kx6oQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_M0yLh30QXkyhtVANhsC4gg">2023-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_OT416jFlgUWPs83yrh0ysg">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Tc_YgzXbu4LzkuZsKsmU5no3A_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Tc_Ydga4oleTk-x6NhTg2q1cQ_1_2">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Tc_vlP3FNEImkeOPFnhrmx0Yw_1_4">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_PoSp81GyxE6_2KUaZ9sLmA">9708 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_au77FcctMUOIuOcIuLDAHA">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_gI1XIHDOGUm_Bhrbcidi6A">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_8JYiLpr3MEiJXVAf6Wuylg">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_eVqJafHtzU6gV5NuxdjWAw">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_Fx3UpzhxzkGBzF5xC76YnQ">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_j8a8rgBV7EG3txS8e1Pvww">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_LnmH6372q0ymUOv4fdkGqA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_q0j95xb16kyf2Fg3Ahq_kw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_5WutMF3BQUaMwP7XE2hqog">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Tc_R2fnw-sIjUWiUYWUMnDAyg_2_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Tc_aI8tM4d9o0K15tI1cZY3LA_2_1">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Tc_qAZeN6yBq0OcHYSNZnBGbw_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ"
      id="Narr_kNcGGEYWcUirjk3CEzqykA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2I/:C#8(-E594-E[@+MS@6:W @KL]0&*_XU\8O50N)0'915TV[W!%496^7V
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ =D1C5Y>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M/Z*A[.9V<L>KZK2^9^S5OCA5C5L8?]#B"U!+ P04    " !V1&-7C?<L6K0
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MJW3:^#-?#>_)YA-02P$"% ,4    " !V1&-7!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '9$8U<Z
M+G%9[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( '9$8U>97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ =D1C5Z)*Q4-4!
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M<R\N<F5L<U!+ 0(4 Q0    ( '9$8U<-8>"'4 $  ,4"   /
M  "  ;03  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !V1&-7C?<L6K0
M  ") @  &@              @ $Q%0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " !V1&-7;J<DO!X!  !7!   $P
M@ $=%@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "@ * (0"  !L%P
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="glyc-20231103x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="glyc-20231103x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995470 - Disclosure - N-2</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cef/role/N2</Role>
      <ShortName>N-2</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>glyc-20231103.xsd</File>
    <File>glyc-20231103_lab.xml</File>
    <File>glyc-20231103_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="glyc-20231103x8k.htm">glyc-20231103x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "glyc-20231103x8k.htm": {
   "nsprefix": "glyc",
   "nsuri": "http://www.glycomimetics.com/20231103",
   "dts": {
    "schema": {
     "local": [
      "glyc-20231103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/2006/xbrldi-2006.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/cef/2023/cef-2023.xsd",
      "https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20231103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20231103_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "glyc-20231103x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 208,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20231103x8k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20231103x8k.htm",
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/cef/role/N2",
     "longName": "995470 - Disclosure - N-2",
     "shortName": "N-2",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "Duration_11_3_2023_To_11_3_2023_5-vkoG-yC0ukPfRmbUdxFQ",
      "name": "dei:EntityFileNumber",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "glyc-20231103x8k.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "cef_AnnualDividendPaymentInitial": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPaymentInitial",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Initial"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherSecurityDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecurityDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Description [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_UnderwritersCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "UnderwritersCompensationPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters Compensation [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Title [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpense3Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense3Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 3 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityLiquidationRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityLiquidationRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liquidation Rights [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualDividendPayment": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPayment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment"
       }
      }
     },
     "auth_ref": []
    },
    "cef_InterestExpensesOnBorrowingsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "InterestExpensesOnBorrowingsPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expenses on Borrowings [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "cef_LongTermDebtPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtPrincipal",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Principal"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherMasterFundExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherMasterFundExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Master Fund Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpensesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_EffectsOfLeverageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeverageTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_FinancialHighlightsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "FinancialHighlightsAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Highlights [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityLiabilitiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Liabilities [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityPreemptiveAndOtherRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityPreemptiveAndOtherRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Preemptive and Other Rights [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpense1Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense1Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 1 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IncentiveAllocationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpense2Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpense2Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": "cef_OtherTransactionExpensesPercent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expense 2 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DistributionsMayReducePrincipalTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DistributionsMayReducePrincipalTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributions May Reduce Principal [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SecurityObligationsOfOwnershipTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityObligationsOfOwnershipTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Obligations of Ownership [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualInterestRateInitialPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRateInitialPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Initial [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualDividendPaymentCurrent": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualDividendPaymentCurrent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Dividend Payment, Current"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PreferredStockRestrictionsArrearageTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PreferredStockRestrictionsArrearageTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Arrearage [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionExpensesPercent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Te": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "cef_PreferredStockRestrictionsOtherTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PreferredStockRestrictionsOtherTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Restrictions, Other [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Subject to Other than Majority Vote [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualInterestRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRatePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RightsLimitedByOtherSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RightsLimitedByOtherSecuritiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualExpensesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "cef_AcquiredFundIncentiveAllocationNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundIncentiveAllocationNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Incentive Allocation, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PrimaryShelfFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PrimaryShelfFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Total Annual Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ManagementFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ManagementFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "cef_ReturnAtMinusFivePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtMinusFivePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Five [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RegisteredClosedEndFundFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RegisteredClosedEndFundFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Closed-End Fund [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_EffectsOfLeverageTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeverageTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtStructuringTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtStructuringTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Structuring [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_PrimaryShelfQualifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PrimaryShelfQualifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary Shelf Qualified [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualCoverageReturnRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualCoverageReturnRatePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Coverage Return Rate [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_BusinessDevelopmentCompanyFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BusinessDevelopmentCompanyFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development Company [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AnnualInterestRateCurrentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AnnualInterestRateCurrentPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Interest Rate, Current [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtMinusTenPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtMinusTenPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Minus Ten [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DividendAndInterestExpensesOnShortSalesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendAndInterestExpensesOnShortSalesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend and Interest Expenses on Short Sales [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IncentiveAllocationMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationMaximumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Maximum [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherSecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Security, Title [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IncentiveFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DistributionServicingFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DistributionServicingFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution/Servicing Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Issuance and Substitution [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IntervalFundFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IntervalFundFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interval Fund [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense1Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense1Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 1 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtDividendsAndCovenantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtDividendsAndCovenantsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Dividends and Covenants [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AcquiredFundFeesAndExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesAndExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense2Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense2Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 2 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtZeroPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtZeroPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Zero [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LoanServicingFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LoanServicingFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Servicing Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_NewCefOrBdcRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NewCefOrBdcRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New CEF or BDC Registrant [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityHeldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityHeldShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Held [Shares]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ReturnAtPlusFivePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtPlusFivePercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Five [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherFeederFundExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherFeederFundExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Feeder Fund Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management Fee not based on Net Assets, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_FeeTableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "FeeTableAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Table [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsCalledPeriodDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledPeriodDate",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Period [Date]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsCalledAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledAmount",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DividendExpenseOnPreferredSharesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendExpenseOnPreferredSharesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Expenses on Preferred Shares [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsCalledTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsCalledTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Called Title"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "cef_ReturnAtPlusTenPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ReturnAtPlusTenPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return at Plus Ten [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ShareholderTransactionExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ShareholderTransactionExpensesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Transaction Expenses [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Liquidating Preference"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpensesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_EffectsOfLeveragePurposeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "EffectsOfLeveragePurposeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of Leverage, Purpose [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WarrantsOrRightsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WarrantsOrRightsExercisePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants or Rights, Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AcquiredFundFeesEstimatedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesEstimatedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees Estimated, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecuritiesTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Securities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "cef_DividendReinvestmentAndCashPurchaseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "DividendReinvestmentAndCashPurchaseFees",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Reinvestment and Cash Purchase Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityAuthorizedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityAuthorizedShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Authorized [Shares]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SharePriceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SharePriceTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OutstandingSecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Title [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_IncentiveAllocationMinimumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "IncentiveAllocationMinimumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Allocation Minimum [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SalesLoadPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SalesLoadPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Load [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesHeadingsNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHeadingsNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Headings, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r14"
     ]
    },
    "cef_OtherTransactionFeesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesCoveragePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesCoveragePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cef_OtherTransactionFeesBasisNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Averaging Method, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionFeesBasisMaximumPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisMaximumPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "auth_ref": []
    },
    "us-gaap_InterestRateRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateRiskMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Rate Risk [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetAssetValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetAssetValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NAV Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "cef_GeneralDescriptionOfRegistrantAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "GeneralDescriptionOfRegistrantAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Description of Registrant [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherExpensesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherExpensesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Annualized, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesCvgPerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesCvgPerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Coverage per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherTransactionFeesBasisMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherTransactionFeesBasisMaximum",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Transaction Fees Basis, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cef_BasisOfTransactionFeesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BasisOfTransactionFeesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Transaction Fees, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Highlights Audited, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesAverageMarketValuePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAverageMarketValuePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Average Market Value per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LowestPriceOrBid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBid",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ProspectusTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ProspectusTable",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus:"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LatestSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestSharePrice",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Share Price (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "cef_HighestPriceOrBid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBid",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cef_OutstandingSecurityNotHeldShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OutstandingSecurityNotHeldShares",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Security, Not Held [Shares]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r14"
     ]
    },
    "cef_ProspectusLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ProspectusLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prospectus [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "cef_LowestPriceOrBidNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBidNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, NAV"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "cef_HighestPriceOrBidNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBidNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, NAV"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13"
     ]
    },
    "cef_HighestPriceOrBidPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "HighestPriceOrBidPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "cef_SecurityTitleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityTitleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Title [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LatestNav": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestNav",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest NAV (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SharePricesNotActualTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SharePricesNotActualTransactionsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Prices Not Actual Transactions [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8"
     ]
    },
    "cef_LowestPriceOrBidPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LowestPriceOrBidPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "cef_NoPublicTradingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NoPublicTradingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Public Trading [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities, Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "glyc_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.glycomimetics.com/20231103",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_NoTradingHistoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NoTradingHistoryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading History [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_LatestPremiumDiscountToNavPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "LatestPremiumDiscountToNavPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Premium (Discount) to NAV [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "cef_SeniorSecuritiesAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cef_SecurityDividendsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityDividendsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Dividends [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13"
     ]
    },
    "cef_CapitalStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "CapitalStockTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_SeniorSecuritiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesAmount",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Amount (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "cef_SecurityVotingRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SecurityVotingRightsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Voting Rights [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cef_ExpenseExampleYears1to3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to3",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 3"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpense3Percent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpense3Percent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": "cef_OtherAnnualExpensesPercent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expense 3 [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_OtherAnnualExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "OtherAnnualExpensesPercent",
     "calculation": {
      "http://xbrl.sec.gov/cef/role/Item3Ae": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Annual Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "cef_NetExpenseOverAssetsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "NetExpenseOverAssetsPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Expense over Assets [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cef_BdcFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "BdcFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BDC File Number"
       }
      }
     },
     "auth_ref": []
    },
    "cef_WaiversAndReimbursementsOfFeesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "WaiversAndReimbursementsOfFeesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Waivers and Reimbursements of Fees [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ExpenseExampleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Securities Involuntary Liquidating Preference per Unit (Deprecated 2023-01-31)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "cef_TotalAnnualExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "TotalAnnualExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Annual Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_AcquiredFundFeesAndExpensesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AcquiredFundFeesAndExpensesPercent",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Fund Fees and Expenses [Percent]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_InvestmentObjectivesAndPracticesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "InvestmentObjectivesAndPracticesTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Objectives and Practices [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ExpenseExampleYear01": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYear01",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Year 01"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "auth_ref": []
    },
    "cef_ExpenseExampleYears1to5": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to5",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 5"
       }
      }
     },
     "auth_ref": []
    },
    "cef_ExpenseExampleYears1to10": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "ExpenseExampleYears1to10",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense Example, Years 1 to 10"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "cef_PurposeOfFeeTableNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "PurposeOfFeeTableNoteTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purpose of Fee Table , Note [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "cef_RiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cef_AllRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "AllRisksMember",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Risks:"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "cef_RiskFactorsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cef/2023",
     "localname": "RiskFactorsTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cef/role/N2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Factors [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-23-017507-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-017507-xbrl.zip
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M&01]<754/81[FD6UJ&<-H:#(>2%K%#6A2)2\T%2PJC9E3<_A9$WP9[?M [
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M_JTIDKJSFV'/@#'H[>UB3NB&A M*TP0&FY)1:&2UO-G 6EYKY,VB;.J2!@:
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MC9[E\Z*&BD#MP->Y;POF'++0U*'%B21BP)"#U3SEL+E:+/@O/0:S8L7[Y>*
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M6<2 N=#?B!4\CH>(I;>4^R@$ ,R)HG<\I,J_C'/(6P)N*BZE?@ZC7,#!RQV
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MQJ1&M;7;L=%N%5$D63%$N0!"UE-*$,\TA(AJ"M'Q8H5^4O00\V0.)&8+TDX
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M576&!T=VLPP'62ETJ0CZ'M1:C#2S0%,M=,G6&=,11K(C+F2Z5>,,TG=*K9R
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M->G[&UEK,%;3DJR*M@H1H^737SA+J214_?6#BJK5Q(YA/#TG!$<,\@#M2TJ
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MUC?V-M&5OP;PI5X;^OQWA-X*[MWWBM##GO F\,\P&?EO_Q]02P$"% ,4
M" !V1&-792!!L/T#  #;#@  $0              @ $     9VQY8RTR,#(S
M,3$P,RYX<V102P$"% ,4    " !V1&-7J !_D^D!  !.!0  %0
M    @ $L!   9VQY8RTR,#(S,3$P,U]L86(N>&UL4$L! A0#%     @ =D1C
M5YY923B\!   YRD  !4              ( !2 8  &=L>6,M,C R,S$Q,#-?
M<')E+GAM;%!+ 0(4 Q0    ( '9$8U?&4P"SS18  ,6N   4
M  "  3<+  !G;'EC+3(P,C,Q,3 S>#AK+FAT;5!+ 0(4 Q0    ( '9$8U?)
M_CZ;<B(  %\= @ 8              "  38B  !G;'EC+3(P,C,Q,3 S>&5X
>.3ED,2YH=&U02P4&      4 !0!- 0  WD0

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
